PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126

Zhu,Junwei; Li,Haomiao; Ma,Jun; Huang,Haibo; Qin,Jianjun; Li,Yin

doi:10.3892/ol.2017.6315

PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126

Authors:
- Junwei Zhu
- Haomiao Li
- Jun Ma
- Haibo Huang
- Jianjun Qin
- Yin Li
View Affiliations

Affiliations: Department of Thoracic Surgery, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China, Department of Gastroenterology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450014, P.R. China
Published online on: June 6, 2017 https://doi.org/10.3892/ol.2017.6315
Pages: 1419-1426
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein tyrosine phosphatase non‑receptor type 9 (PTPN9), also named PTP-MEG2, is an important member of the protein tyrosine phosphatase family that is involved in variety of human diseases. However, the role of PTPN9 in esophageal squamous cell carcinoma (ESCC) remains to be established. The present evaluated the potential effect and underlying mechanism of action of PTPN9 in ESCC. Immunohistochemistry was performed to detect PTPN9 protein expression in 84 ESCC tumor specimens and 30 normal esophageal tissues. The association between positive expression of PTPN9 and clinicopathological features and prognosis was analyzed. The prognostic role of PTPN9 was further investigated using multivariate regression analysis. PTPN9‑small interfering RNA and microRNA (miR‑126)‑mimics were transfected into Eca109 cells to construct PTPN9 silencing and an miR‑126 ectopic expression cell model. Reverse transcription‑quantitative polymerase chain reaction, western blot analysis, cell counting kit‑8, Transwell assays and flow cytometry were used to investigate the role of PTPN9 in the process of ESCC progression and its potential downstream signaling pathway. Immunohistochemical analysis revealed that PTPN9 was upregulated in ESCC tumor specimens compared with normal esophageal tissues. The χ2 test indicated that positive expression of PTPN9 was correlated with tumor node metastasis stage, tumor classification and node classification. Patients with PTPN9 positive expression had shorter survival time, compared with those that were PTPN9 negative. Multivariate regression analysis with the Cox proportional hazards regression model revealed that PTPN9 expression was a prognostic factor of overall survival for patients with ESCC. Using RNA interference, the present study demonstrated that knockdown of PTPN9 significantly suppressed cell proliferation and invasion in Eca109. Additionally, it was hypothesized that miR‑126, described as a tumor suppressor in ESCC, may act at least in part via its inhibition of PTPN9 at the post‑transcriptional level. To the best of our knowledge, this is the first study to demonstrate that PTPN9 is overexpressed in ESCC and associated with poor survival, and may therefore be important in the pathogenesis of ESCC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen WQ, Zheng RS, Zhang SW, Zeng HM and Zou XN: The incidences and mortalities of major cancers in China, 2010. Chin J Cancer. 33:402–405. 2014.PubMed/NCBI
3	Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 23:233–242. 2013. View Article : Google Scholar : PubMed/NCBI
4	Matsushima K, Isomoto H, Kohno S and Nakao K: MicroRNAs and esophageal squamous cell carcinoma. Digestion. 82:138–144. 2010. View Article : Google Scholar : PubMed/NCBI
5	Kruger JM, Fukushima T, Cherepanov V, Borregaard N, Loeve C, Shek C, Sharma K, Tanswell AK, Chow CW and Downey GP: Protein-tyrosine phosphatase MEG2 is expressed by human neutrophils. Localization to the phagosome and activation by polyphosphoinositides. J Biol Chem. 277:2620–2628. 2002. View Article : Google Scholar : PubMed/NCBI
6	Xu MJ, Sui X, Zhao R, Dai C, Krantz SB and Zhao ZJ: PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. Blood. 102:4354–4360. 2003. View Article : Google Scholar : PubMed/NCBI
7	Huynh H, Wang X, Li W, Bottini N, Williams S, Nika K, Ishihara H, Godzik A and Mustelin T: Homotypic secretory vesicle fusion induced by the protein tyrosine phosphatase MEG2 depends on polyphosphoinositides in T cells. J Immunol. 171:6661–6671. 2003. View Article : Google Scholar : PubMed/NCBI
8	Krugmann S, Anderson KE, Ridley SH, Risso N, McGregor A, Coadwell J, Davidson K, Eguinoa A, Ellson CD, Lipp P, et al: Identification of ARAP3, a novel PI3K effector regulating both Arf and Rho GTPases, by selective capture on phosphoinositide affinity matrices. Mol Cell. 9:95–108. 2002. View Article : Google Scholar : PubMed/NCBI
9	Zhang D, Marlin MC, Liang Z, Ahmad M, Ashpole NM, Sonntag WE, Zhao ZJ and Li G: The protein tyrosine phosphatase MEG2 regulates the transport and signal transduction of tropomyosin receptor kinase A. J Biol Chem. 291:23895–23905. 2016. View Article : Google Scholar : PubMed/NCBI
10	Huynh H, Bottini N, Williams S, Cherepanov V, Musumeci L, Saito K, Bruckner S, Vachon E, Wang X, Kruger J, et al: Control of vesicle fusion by a tyrosine phosphatase. Nat Cell Biol. 6:831–839. 2004. View Article : Google Scholar : PubMed/NCBI
11	Cho CY, Koo SH, Wang Y, Callaway S, Hedrick S, Mak PA, Orth AP, Peters EC, Saez E, Montminy M, et al: Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling. Cell Metab. 3:367–378. 2006. View Article : Google Scholar : PubMed/NCBI
12	Zhang S, Liu S, Tao R, Wei D, Chen L, Shen W, Yu ZH, Wang L, Jones DR, Dong XC and Zhang ZY: A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes. J Am Chem Soc. 134:18116–18124. 2012. View Article : Google Scholar : PubMed/NCBI
13	Yuan T, Wang Y, Zhao ZJ and Gu H: Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. J Biol Chem. 285:14861–14870. 2010. View Article : Google Scholar : PubMed/NCBI
14	Su F, Ren F, Rong Y, Wang Y, Geng Y, Wang Y, Feng M, Ju Y, Li Y, Zhao ZJ, et al: Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res. 14:R382012. View Article : Google Scholar : PubMed/NCBI
15	Du WW, Fang L, Li M, Yang X, Liang Y, Peng C, Qian W, O'Malley YQ, Askeland RW, Sugg SL, et al: MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J Cell Sci. 126:1440–1453. 2013. View Article : Google Scholar : PubMed/NCBI
16	Hao Q, Samten B, Ji HL, Zhao ZJ and Tang H: Tyrosine phosphatase PTP-MEG2 negatively regulates vascular endothelial growth factor receptor signaling and function in endothelial cells. Am J Physiol Cell Physiol. 303:C548–C553. 2012. View Article : Google Scholar : PubMed/NCBI
17	Hromadnikova I, Kotlabova K, Hympanova L and Krofta L: Gestational hypertension, preeclampsia and intrauterine growth restriction induce dysregulation of cardiovascular and cerebrovascular disease associated microRNAs in maternal whole peripheral blood. Thromb Res. 137:126–140. 2016. View Article : Google Scholar : PubMed/NCBI
18	Gu L, Li H, Chen L, Ma X, Gao Y, Li X, Zhang Y, Fan Y and Zhang X: MicroRNAs as prognostic molecular signatures in renal cell carcinoma: A systematic review and meta-analysis. Oncotarget. 6:32545–32560. 2015.PubMed/NCBI
19	Meister J and Schmidt MH: miR-126 and miR-126*New players in cancer. ScientificWorldJournal. 10:2090–2100. 2010. View Article : Google Scholar : PubMed/NCBI
20	Shang AQ, Xie YN, Wang J, Sun L, Wei J, Lu WY, Lan JY, Wang WW, Wang L and Wang LL: Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: A case-control study. Neoplasma. 64:2017.(Epub ahead of print). View Article : Google Scholar
21	Yuan W, Guo YQ, Li XY, Deng MZ, Shen ZH, Bo CB, Dai YF, Huang MY, Yang ZY, Quan YS, et al: MicroRNA-126 inhibits colon cancer cell proliferation and invasion by targeting the chemokine (C-X-C motif) receptor 4 and Ras homolog gene family, member A, signaling pathway. Oncotarget. 7:60230–60244. 2016.PubMed/NCBI
22	Wang CZ, Yuan P and Li Y: MiR-126 regulated breast cancer cell invasion by targeting ADAM9. Int J Clin Exp Pathol. 8:6547–6553. 2015.PubMed/NCBI
23	Jiang R, Zhang C, Liu G, Gu R and Wu H: MicroRNA-126 inhibits proliferation, migration, invasion and EMT in osteosarcoma by targeting ZEB1. J Cell Biochem. 2017.(Epub ahead of print). View Article : Google Scholar
24	Wang J, Zhou Y, Fei X, Chen X, Yan J, Liu B and Zhu Z: ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126. Oncol Rep. 37:2033–2040. 2017.PubMed/NCBI
25	Zhu X, Li H, Long L, Hui L, Chen H, Wang X, Shen H and Xu W: miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai). 44:519–526. 2012. View Article : Google Scholar : PubMed/NCBI
26	Png KJ, Halberg N, Yoshida M and Tavazoie SF: A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 481:190–194. 2011. View Article : Google Scholar : PubMed/NCBI
27	Li Z, Li N, Wu M, Li X, Luo Z and Wang X: Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. Mol Cell Biochem. 381:233–242. 2013. View Article : Google Scholar : PubMed/NCBI
28	Yue S, Shi H, Han J, Zhang T, Zhu W and Zhang D: Prognostic value of microRNA-126 and CRK expression in gastric cancer. Onco Targets Ther. 9:6127–6135. 2016. View Article : Google Scholar : PubMed/NCBI
29	Huang X, Gschweng E, van Handel B, Cheng D, Mikkola HK and Witte ON: Regulated expression of microRNAs-126/126* inhibits erythropoiesis from human embryonic stem cells. Blood. 117:2157–2165. 2011. View Article : Google Scholar : PubMed/NCBI
30	Wittekind C: 2010 TNM system: On the 7th edition of TNM classification of malignant tumors. Pathologe. 31:331–332. 2010. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
32	Li H, Meng F, Ma J, Yu Y, Hua X, Qin J and Li Y: Insulin receptor substrate-1 and Golgi phosphoprotein 3 are downstream targets of miR126 in esophageal squamous cell carcinoma. Oncol Rep. 32:1225–1233. 2014.PubMed/NCBI
33	Arnal MJ Domper, Ferrández Arenas Á and Lanas Arbeloa Á: Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 21:7933–7943. 2015. View Article : Google Scholar : PubMed/NCBI
34	Hu B, Yan X, Liu F, Zhu C, Zhou H, Chen Y, Liu J, Gu X, Ni R and Zhang T: Downregulated expression of PTPN9 contributes to human hepatocellular carcinoma growth and progression. Pathol Oncol Res. 22:555–565. 2016. View Article : Google Scholar : PubMed/NCBI
35	Hong Y, Liang H, Uzair-Ur-Rehman, Wang Y, Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, et al: miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer. Sci Rep. 6:374212016. View Article : Google Scholar : PubMed/NCBI
36	Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK: miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
37	Nie ZC, Weng WH, Shang YS, Long Y, Li J, Xu YT and Li Z: MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway. Int J Clin Exp Pathol. 8:4745–4754. 2015.PubMed/NCBI
38	Liu R, Gu J, Jiang P, Zheng Y, Liu X, Jiang X, Huang E, Xiong S, Xu F, Liu G, et al: DNMT1-microRNA126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9-EGFR-AKT signaling. Clin Cancer Res. 21:854–863. 2015. View Article : Google Scholar : PubMed/NCBI
39	Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ, Wang TY, Li HC and Wu XN: Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett. 5:1639–1642. 2013.PubMed/NCBI